Analysts Issue Forecasts for Krystal Biotech Q1 Earnings

Krystal Biotech, Inc. (NASDAQ:KRYS) – Analysts at William Blair cut their Q1 2025 earnings per share (EPS) estimates for Krystal Biotech in a research note issued on Wednesday, April 2nd. William Blair analyst S. Corwin now forecasts that the company will post earnings of $1.31 per share for the quarter, down from their prior forecast of $1.47. The consensus estimate for Krystal Biotech’s current full-year earnings is $6.14 per share. William Blair also issued estimates for Krystal Biotech’s Q2 2025 earnings at $1.47 EPS, Q4 2025 earnings at $2.03 EPS, FY2025 earnings at $6.65 EPS, Q1 2026 earnings at $1.60 EPS, Q2 2026 earnings at $1.94 EPS and FY2026 earnings at $9.03 EPS.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.29 by $0.23. The company had revenue of $91.10 million during the quarter, compared to analyst estimates of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The company’s revenue for the quarter was up 116.4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.30 EPS.

KRYS has been the subject of several other research reports. Chardan Capital boosted their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a report on Thursday, February 20th. HC Wainwright reissued a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a research note on Friday, February 28th. Citigroup raised their price target on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research report on Thursday, February 20th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. Finally, Jefferies Financial Group started coverage on Krystal Biotech in a research note on Wednesday, March 5th. They set a “buy” rating and a $245.00 target price for the company. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Krystal Biotech currently has an average rating of “Buy” and a consensus target price of $220.00.

Krystal Biotech Stock Performance

Shares of NASDAQ KRYS opened at $166.01 on Monday. Krystal Biotech has a 52-week low of $141.72 and a 52-week high of $219.34. The stock has a market cap of $4.78 billion, a P/E ratio of 55.52 and a beta of 0.75. The firm has a 50 day moving average price of $173.40 and a 200 day moving average price of $172.87.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB bought a new stake in Krystal Biotech during the third quarter worth $40,000. GF Fund Management CO. LTD. bought a new stake in shares of Krystal Biotech during the 4th quarter worth $95,000. Covestor Ltd boosted its stake in Krystal Biotech by 972.7% in the fourth quarter. Covestor Ltd now owns 708 shares of the company’s stock valued at $111,000 after buying an additional 642 shares in the last quarter. Avanza Fonder AB bought a new position in Krystal Biotech in the fourth quarter valued at about $119,000. Finally, KBC Group NV grew its position in Krystal Biotech by 46.3% in the fourth quarter. KBC Group NV now owns 939 shares of the company’s stock valued at $147,000 after acquiring an additional 297 shares during the last quarter. 86.29% of the stock is owned by institutional investors.

Insider Activity at Krystal Biotech

In related news, CAO Kathryn Romano sold 750 shares of the firm’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the transaction, the chief accounting officer now owns 12,604 shares in the company, valued at approximately $2,208,472.88. This trade represents a 5.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the transaction, the insider now directly owns 1,463,711 shares of the company’s stock, valued at approximately $260,233,178.69. This trade represents a 1.68 % decrease in their position. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by corporate insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).